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Abstract
 
Parasite-encoded variant surface antigens (VSAs) like the 
 
var
 
 gene–encoded 
 
Plasmodium fal-
ciparum
 
 erythrocyte membrane protein 1 (PfEMP1) family are responsible for antigenic variation
and infected red blood cell (RBC) cytoadhesion in 
 
P. falciparum
 
 malaria. Parasites causing severe
malaria in nonimmune patients tend to express a restricted subset of VSA (VSA
 
SM
 
) that differs
from VSA associated with uncomplicated malaria and asymptomatic infection (VSA
 
UM
 
). We
compared 
 
var
 
 gene transcription in unselected 
 
P. falciparum
 
 clone 3D7 expressing VSA
 
UM 
 
to in
vitro–selected sublines expressing VSA
 
SM 
 
to identify PfEMP1 responsible for the VSA
 
SM 
 
phe-
notype. Expression of VSA
 
SM 
 
was accompanied by up-regulation of Group A 
 
var
 
 genes. The
most prominently up-regulated Group A gene (
 
PFD1235w/MAL7P1.1
 
) was translated into a
protein expressed on the infected RBC surface. The proteins encoded by Group A 
 
var
 
 genes,
such as 
 
PFD1235w/MAL7P1.1
 
, appear to be involved in the pathogenesis of severe disease and
are thus attractive candidates for a vaccine against life-threatening 
 
P. falciparum
 
 malaria.
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var
 
 gene • 
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Introduction
 
Plasmodium falciparum
 
 is the most pathogenic malaria parasite
and a major cause of morbidity and mortality among chil-
dren in sub-Saharan Africa. The virulence of 
 
P. falciparum
 
has been linked to its expression of variant surface antigens
(VSAs) that subvert acquisition of protective immunity and
mediate infected RBC sequestration (for review see reference
1). Severe and life-threatening falciparum malaria is associated
with parasites expressing a restricted and antigenically con-
served VSA subset (VSA
 
SM
 
; 2–4). VSA
 
SM 
 
expression appears
to confer a selective advantage on parasites in nonimmune
individuals, perhaps by allowing particularly efficacious in-
fected RBC sequestration and high growth rates (5). As
VSA
 
SM
 
-specific immunity is acquired, this advantage gradually
gets smaller. Survival rates of parasites expressing less virulent
and more diverse VSAs (VSA
 
UM
 
) eventually surpass those
of VSA
 
SM
 
-expressing parasites, causing VSA
 
UM
 
-expressing
parasites to dominate infections in semi-immune individuals
(5). This scenario makes it theoretically possible to protect
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nonimmune children against severe and complicated ma-
laria by accelerating acquisition of VSA
 
SM
 
-specific immu-
nity through vaccination.
 
P. falciparum
 
 erythrocyte membrane protein 1 (PfEMP1)
is the best characterized VSA family. PfEMP1 molecules
are encoded by the 
 
var
 
 family comprising 40–60 highly di-
verse genes per haploid genome (6–8). Any single parasite
expresses one PfEMP1 variant on the infected RBC surface
(9, 10), but expression can switch at each reinvasion cycle
(11, 12). Previous efforts to link PfEMP1 expression to par-
ticular clinical syndromes have been foiled by the extensive
intergenomic and intragenomic variation of 
 
var
 
 genes in field
isolates, simultaneous transcription of several 
 
var
 
 genes, and
technical difficulties such as primer bias (13–15).
We have combined the availability of the entire genome
sequence and the structural characteristics of the 
 
var
 
 genes in
the 
 
P. falciparum
 
 clone 3D7 (16–18) with the capacity to con-
trol the VSA phenotype of this clone by in vitro antibody se-
lection (19) or selection for adhesion to transformed human
bone marrow endothelial cells (TrHBMECs; 20 and unpub-
lished data) to investigate the relationship between VSA phe-
notype, 
 
var
 
 gene transcription, and PfEMP1 expression.
 
Materials and Methods
 
Malaria Parasites and In Vitro Selection Procedure.
 
The 
 
P. falcip-
arum
 
 clone 3D7 was cultured in 0 Rh
 
 
 
RBCs as previously de-
scribed (21). Repeated rounds of panning on DynaBeads coated
by IgG from two plasma pools (SM1 and SM2) from semi-
immune Ghanaian children (22) and one plasma pool (SM3)
from semi-immune Tanzanian children (23) were used to select
3D7 parasites expressing VSAs that were highly recognized by
IgG in these plasma pools (19).
Standard panning techniques (24) were used to select 3D7
asexual parasites for adhesiveness to TrHBMECs (20, 25). After
three rounds of selection followed by cryo preservation and re-
covery, the ability of the selected subline and the parental culture
to adhere to TrHBMEC (5,000–20,000/well) was compared.
On average (six experiments), selected 3D7 bound 69 infected
RBCs/100 TrHBMECs compared with 17.5 infected RBCs/
100 TrHBMECs for the unselected parental parasites (P 
 

 
0.0008; Student’s 
 
t 
 
test).
Flow cytometry (21) was used to verify that each of the four se-
lected sublines expressed VSA
 
SM
 
-type VSAs, i.e., had a plasma IgG
recognition pattern resembling that of VSAs expressed by 
 
P. falcip-
arum
 
 parasites isolated from children with severe malaria (2, 3). The
genotypic identity of 3D7 and the selected sublines was regularly
verified by PCR at the polymorphic 
 
msp1
 
, 
 
msp2
 
, and 
 
glurp
 
 loci (3).
In addition, parasites were isolated on days 8, 9, and 10 from a
Dutch volunteer exposed on day 0 to mosquitoes infected by 
 
P.
falciparum
 
 isolate NF54 (26) as part of ongoing studies of experi-
mental infections (27). These parasites were cultured in vitro for
27 (day 8 and day 9 isolates) or 33 d (day 10 isolate) to obtain suf-
ficient parasites for DNA/RNA analysis. Experiments involving
samples of human origin received ethical clearance from the Na-
tional Institute for Medical Research, Dar es Salaam, Tanzania,
and the Ethical Committee of the University Medical Centre,
Nijmegen, Netherlands.
 
DNA/RNA Extraction and cDNA Synthesis.
 
RBCs infected
by trophozoite/schizont-stage parasites (36–48 h after invasion)
from in vitro cultures were isolated by exposure to a strong mag-
netic field (21). In some experiments, the purified infected RBCs
were cultured overnight to obtain cultures uniformly infected by
ring-stage (30 h) parasites. These time points have previously been
shown to be optimal for studies of 
 
var
 
 gene transcription (28).
Genomic DNA was isolated from infected RBCs by Nu-
cleospin purification kits (BD Biosciences) and total RNA was
prepared using Trizol (Invitrogen) as recommended by the man-
ufacturers and treated with DNase1 (Invitrogen) for 15 min at
37
 

 
C. Absence of DNA in RNA samples was confirmed by stable
base fluorescence after 40 cycles of real-time PCR with 
 
seryl-
tRNA synthetase
 
 primers (28). Superscript II was used to reverse
transcribe DNA-free RNA primed with random hexamer prim-
ers (Invitrogen) at 25
 

 
C for 10 min and 42
 

 
C for 50 min followed
by 70
 

 
C for 15 min.
 
Quantitative Real-time PCR.
 
Quantitative real-time PCR was
performed using a Rotorgene thermal cycler system (Corbett
Research) and real-time PCR-optimized and gene-specific prim-
ers for each of 59 full-length 
 
var
 
 genes and a pseudogene in the 
 
P.
falciparum
 
 3D7 genome (28 and see Table S1, available at http://
www.jem.org/cgi/content/full/jem.20040274/DC1).
Reactions were performed in 20-
 

 
l volumes using Quanti-
Tect SYBR Green PCR Master Mix (QIAGEN) and 0.5 mM
primers as previously described (28). Quantification was per-
formed using Rotorgene software version 4.6. The housekeeping
gene 
 
seryl-tRNA synthetase
 
, which shows a uniform transcription
profile in different parasite isolates and an unchanged pattern
throughout the parasite life cycle, was used as an endogenous
control as previously described (28), and used for calculations of
fold changes in 
 
var
 
 gene transcription by the 
 

 
CT method
(User Bulletin no. 2; Applied Biosystems). We have previously
verified the equality of the efficiency of the target (
 
var
 
) and refer-
ence (
 
seryl-tRNA synthetase
 
) amplification using the primer set on
serial dilutions of genomic DNA (28).
 
DNA Cloning, Standard Curve, and Absolute Quantification.
 
Genes (
 
PF11_0521
 
,
 
 PFL0030c
 
, 
 
PFL1950w
 
,
 
 PFL005w
 
,
 
PF13_003
 
,
 
 PFB1055c
 
,
 
 PFD1235w/MAL7P1.1
 
,
 
 PFE1640w
 
,
 
PFI1830
 
, 
 
PF08_0107
 
,
 
 MAL6P1.314
 
,
 
 MAL6P1.316
 
,
 
 PFD0995c
 
,
 
PFA0015c
 
, and 
 
seryl-tRNA synthetase
 
) used for absolute quantifi-
cation were PCR amplified, ligated into the pCR2.1 TOPO
vector, and transformed into 
 
Escherichia coli
 
 TOPO10 cells (TA
Cloning System; Invitrogen). Plasmids were purified using
QIAGEN Miniprep spin columns (QIAGEN) and the identity of
inserts was verified by subsequent sequencing on an ABI Prism
310 (PerkinElmer) using the Big Dye terminator reaction mix,
ABI Prism proofreading and translation software, and the 
 
P. falcip-
arum
 
 3D7 genome database (http://www.plasmodb.org).
Triplicate real-time measurements were made for each plasmid
dilution (5 
 
 
 
10
 
8 
 
to 5 
 
 
 
10
 
0
 
 
 
template copies) and a best fit stan-
dard curve was generated (28). The standard curves were linear
across a range of seven logs of DNA concentrations with correla-
tion coefficients between 0.9779 and 0.9969. The detection limit
of the system was 
 

 
20 copies (unpublished data). The coefficient
of variance was calculated as 100
 
*
 
 (standard deviation of the
mean). RT-PCR was performed as described using 1 
 
g total
RNA in a total volume of 40 l, of which 0.5 l was subse-
quently used for real-time PCR. Absolute values were calculated
from the standard curves.
Identification of Sequences Related to PFD1235w/MAL7P1.1.
PFD1235w/MAL7P1.1-like var genes were PCR amplified from
genomic DNA of Ghanaian P. falciparum field isolates (BM021
and BM048), cloned, and sequenced. The following primers
used were: sense GTATGGCATCGTAACGCA and antisense
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AGAAGTCTTTGTATGACT. Nucleotide sequence data re-
ported in this paper are available from GenBank/EMBL/DDBJ
under accession nos. AY584238 and AY584239.
Northern Blotting. For Northern blotting, 10 g total RNA
were separated in a standard denaturing MOPS formaldehyde
agarose gel and transferred to positively charged nylon mem-
branes overnight (29, 30). RNA was cross-linked to the mem-
brane by baking for 30 min at 120C. Digoxigenin (DIG)-labeled
RNA probes were generated using the DIG RNA labeling kit
(Roche). Hybridization, washing, and detection were performed
according to the manufacturer’s recommendations with a hybrid-
ization temperature of 65C in DIG Easy Hyb buffer (Roche).
Immunoblot Analysis. SDS-extracted trophozoite/schizont-
stage–infected RBCs were reduced and electrophoresed in the
Laemmli sodium dodecyl sulfate PAGE system (29). Immuno-
blots were prepared on PVDF membranes by semidry blotting
using standard methods. Binding sites were blocked in Tris-buff-
ered saline Tween (TBS-T) containing 5% skimmed milk. Blots
were probed with preimmune mouse sera, antiserum was raised
against a recombinant protein from the intracellular acidic seg-
ment ATS of PfEMP1 genes, and Duffy binding–like domain
(DBL)5-	 of PFD1235w/MAL7P1.1 was diluted 1:100 in TBS-
T. Bound antibody was detected with relevant IgG alkaline
phosphatase–conjugated antibody (DakoCytomation) and blots
were developed using NBT (p-nitroblue tetrazolium phosphate;
Sigma-Aldrich) and BCIP (5-bromo-4-chloro-3-indolylphos-
phate; Sigma-Aldrich) as substrates.
Protein Expression. The cysteine-rich interdomain region
(CIDR)1-
 and DBL5-	 of PFD1235w/MAL7P1.1 were sub-
cloned into the pGEX-4T1 vector (Amersham Biosciences)
by PCR using the following domain-specific oligonucleotide
primers: CIDR1-
Fw: 5-CGGAATTCGACGCTAAAACTG-
ATAGTA-3; CIDR1-
Rv: 5-ATAAGAATGCGGCCGC-
ACATATATCGCCATTCAACG-3; DBL5-	Fw: 5-CGG-
AATTCAGTCTCAATGCCGCATGTG-3; and DBL5-	Rv:
5-ATAAGAATGCGGCCGCTCTACAATGTCTGCACA-
3. A conserved sequence of the intracellular acidic segment
ATS was subcloned into the pGEX-4T1 vector by PCR using
the following oligonucleotide primers: ATS-Fw: 5-CGGAAT-
TCAAAACAAAATCATCAGTAG-3; ATS-Rv: 5-ATAAG-
AATGCGGCCGCGTTGATTACCACTTAATGTG-3 (EcoRI
site, underlined; NotI site, underlined italics). The proteins were
expressed as fusion proteins at the carboxy terminus of glu-
tathione S-transferase (GST) from Schistosoma japonicum (31) and
purified by affinity chromatography on glutathione sepharose
4B (Amersham Biosciences). The DBL5-	 of PFD1235w/
Table I. Copy Number of Selected var Genes and seryl-tRNA synthetase Transcripts in Unselected and VSAUM-expressing 3D7 and 3D7 
after Antibody Selection for VSASM Expression
Trophozoite/schizont-stage parasites
(36–48 h after invasion)
Ring-stage parasites
(30 h after invasion)
Clustera Primerb Gene Unselected Antibody-selected
Fold
change Unselected Antibody-selected
Fold
change
Copies CVc Copies CVc Copies CVc Copies CVc
A
8 PF11_0521 426 11 7,119 27 16.7 12,570 31 84,341 29 6.7
20 PF13_0003 1,797 7 6,129 20 3.4 77,934 13 179,746 9 2.3
35 PFD1235w/MAL7P1.1 2,931 20 29,941 13 10.2 101,417 27 1,152,758 12 11.4
67 MAL6P1.314 3,145 13 19,356 14 6.2 87,130 19 767,747 8 8.8
97 PFA0015c 77,890 12 1,333 30 58.4 155,151 21 18,419 14 8.4
B/A 94 MAL6P1.316 13,742 15 36,637 24 2.7 247,156 29 1,057,056 28 4.3
B
18 PFL0005w 15 21 1,106 23 73.7 928 12 13,769 23 14.8
21 PFB1055c 64 16 2,533 12 39.6 5,272 22 26,070 5 4.9
58 PFI1830c 79,111 39 59,860 22 1.3 18,600 15 13,124 12 1.4
B/C 12 PFL1950w 226 22 524 8 2.3 13,236 19 19,053 24 1.4
C
66 PF08_0107 82,211 33 5,590 15 16.3 993,679 23 58,130 17 17.1
95 PFD0995c 23,415 19 491 12 47.7 567,205 19 9,148 19 62
var2
10 PFL0030c 907 14 12,562 19 14 12,905 30 127,631 30 9.9
var1 37 PFE1640w 12,279 21 14,239 10 1.2 8,224 17 9,111 30 1.1
seryl-tRNA synthetase 609,533 16 609,533 16 1 643,271 20 643,271 20 1
aDescribed in reference 18.
bDescribed in reference 32 and Table S1.
cCoefficient of variation (%) between three different quantification experiments.
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MAL7P1.1 was cloned into the pBAD-TOPO vector (In-
vitrogen) using the following primers: DBL-5	Fw: 5-CGG-
AATTCAGTCTCAATGCCGCATGTG-3; DBL5-	Rv: 5-
TCTACAATGTCTGGCACA-3. For production of carboxy
terminally V5 epitope and histidine-tagged protein, the DBL5-	
insert was excised by EcoRI and PmeI digestion and then sub-
cloned into the EcoRI and blunt-ended BglII sites of the Baculo-
virus transfer vector pAcGP67-A (BD Biosciences). Recombinant
Baculovirus were generated by cotransfection of the pAcGP67-A-
DBL5-	 construct gene and Bsu36I-linearized Bakpak6 Baculo-
virus DNA (BD Biosciences) into insect Sf9 cells. Recombinant
DBL5-	 product was expressed by infection of insect High Five
cells with recombinant Baculovirus. DBL5-	 protein was purified
from culture supernatants on Co2 metal chelate agarose columns
and eluted with 25 mM Hepes-KOH, pH 7.6, 0.5 mM MgCl2,
0.5 mM DTT, 100 mM NaCl, 10% glycerol, and 100 mM
imidazole.
Generation of Antisera. All procedures complied with Euro-
pean or national regulations. Antibodies to ATS expressed in E.
coli– and Baculovirus-expressed DBL5-	 were raised in BALB/c
mice by subcutaneous injection of 5 g protein in complete
Freund’s adjuvant followed by several boosters of ATS and DBL5-	
in incomplete Freund’s adjuvant.
Immunostaining, Flow Cytometry, and Microscopy. Immuno-
staining and flow cytometry were performed as previously
described (21) with some modifications. In brief, 2.5  105
MACS-purified, ethidium bromide–labeled infected RBCs were
incubated for 1 h in 20 l murine sera or for 30 min in 5 l hu-
man sera depleted for anti–human RBC antibodies. For immu-
nostaining with murine sera, infected RBCs were sequentially
exposed to 100 l of 1:25 goat anti–mouse Ig (DakoCytoma-
tion), biotinylated anti–goat Ig (DakoCytomation), and 1:200
FITC-conjugated streptavidin (DakoCytomation) for 30 min
each. For immunostaining with human sera, infected RBCs were
incubated in 100 l of 1:25 biotinylated anti–human IgG (Dako-
Cytomation) followed by 1:2,000 FITC-conjugated streptavidin
for 30 min each. For confocal microscopy, wet mounts of immu-
nostained parasites and a Carl Zeiss MicroImaging, Inc. scanning
microscope were used. Trypsin treatment was performed as pre-
viously described (32). Cells were washed once in PBS, incu-
bated in 10 vol of 100 g/ml TPCK-treated trypsin (Amersham
Biosciences) in PBS for 10 min at 37C. The reaction was
Figure 1. Fold changes in var gene
transcription by late-stage (36–48 h
after invasion) P. falciparum 3D7 before
and after antibody selection of para-
sites for selection of VSASM-type anti-
gens using DynaBeads coated with
IgG from three different pools of
plasma from semi-immune African
children (SM1, SM2, and SM3; a–c)
and for adhesion to TrHBMEC (d;
see Materials and Methods for details).
Transcription levels were measured
using real-time PCR and primers
specific for 59 var genes and 1
pseudogene (reference 28 and Table
S1). Experiments with SM1 were
repeated five times and results are
shown as means  SD. Solid bars in-
dicate highly transcribed var genes.
These genes had the 15 lowest Ct
values in selected and/or unselected
3D7. A threefold change in var gene
transcription (dashed lines) was arbi-
trarily defined as the cut off for bio-
logically significant changes in var
gene transcription. Primer identity
and calculation of selection-induced
var gene transcription is described in
Materials and Methods and reference
28. The grouping of var genes is de-
scribed in reference 18.
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stopped with 1 vol of 2 mg/ml soybean trypsin inhibitor (Sigma-
Aldrich) in RPMI 1640/5% Albumax.
ELISA. Plasma samples from 20 children (3 to 4 and 10 to 11
yr old) and 10 adults (18 to 19 yr old) living in Mgome village in
the Tanga region of Tanzania were used for ELISA analysis of anti-
body responses to purified recombinant GST proteins (33). Control
plates were coated with GST alone. The mean ELISA unit plus 2
standard deviations obtained with sera from 13 Danish blood donors
without malaria exposure was used as negative cut off value (34).
Competition ELISA. Competition ELISA was performed us-
ing recombinant CIDR1-
 domains of PFD1235w/MAL7P1.1
and var1 (PFE1640w) and three different plasma samples with
high, medium, and low antibody reactivity to these proteins.
Blocking of plasma was performed using 0.1, 1, 5, and 10 g/ml
recombinant protein for 2 h at room temperature. The test plasma
samples were diluted at 1:50 and tested as described above.
Online Supplemental Material. Primers for quantitative real-
time PCR are shown in Table S1, which is available at http://
www.jem.org/cgi/content/full/jem.20040274/DC1.
Results
Group A var Genes Are Up-regulated in 3D7 Selected for Ex-
pression of VSASM-type Antigens. Parasites associated with
severe malaria express VSAs (VSASM) that are recognized at
high levels by plasma IgG of most semi-immune children,
whereas parasites causing uncomplicated malaria infection
tend to express VSAs (VSAUM) that are recognized less of-
ten and at lower levels (2, 3). Among unselected 3D7 para-
sites, most express VSAUM with a small minority expressing
VSASM (19). However, the dominating VSA phenotype
changes to VSASM after selection of 3D7 using DynaBeads
coated with IgG from semi-immune children (19) or adhe-
sion to TrHBMEC. This cell line does not express scaven-
ger receptor CD36 and thus is unlikely to bind VSAUM-
expressing parasites (25).
We compared var gene transcription in unselected and
VSASM-expressing selected 3D7 using primer sets targeting
Figure 2. Changes in var gene transcription in syn-
chronized ring-stage (30 h) P. falciparum 3D7 after anti-
body selection with the SM1 and SM2 pools (a and b)
or selection for adhesion to TrHBMEC (c) as described
in the legend for Fig. 1. A fold-change of two (dotted
lines) was defined as the cut off for biological interesting
changes in var gene transcription.
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each of the 60 var genes in 3D7 (Table S1, which is available
at http://www.jem.org/cgi/content/full/jem.20040274/
DC1; references 16 and 28). 4 (PF13_0003, PFD1235w/
MAL7P1.1, MAL6P1.314, and MAL6P1.316) of the 15
most highly transcribed var genes were up-regulated in
late trophozoites/schizonts after antibody selection–induced
change from VSAUM to VSASM expression, whereas 4
other var genes (PF08_0107, PFD0995c, PFA0015c, and
PFL1955w) were down-regulated (Fig. 1). These changes
were consistently observed after antibody selection of 3D7
with three different plasma pools from West (Fig. 1, a and
b) and East Africa (Fig. 1 c). Comparable results were ob-
tained after selection for binding to TrHBMEC (Fig. 1 d),
although these parasites also showed high transcription of
MAL7P1.55. Ring-stage parasites showed similar patterns,
although three additional genes (PF11_0008, PF11_0521,
and PFL0030c) were up-regulated in response to selection
for VSASM expression (Fig. 2).
Most of the seven up-regulated var genes belong to the
Group A var cluster and encode high mol wt PfEMP1,
whereas one of the up-regulated genes belongs to the
Group B/A cluster and encodes a relatively large PfEMP1
with a complex domain structure (16, 18). In contrast, two
out of three of the down-regulated genes belong to the
Group C cluster, encoding relatively small four-domain
PfEMP1 molecules (16, 18).
To confirm the above results, we measured mRNA
copy numbers of highly transcribed var genes that were sig-
nificantly up-regulated (PF11_0521, PFL0030c, PF13_0003,
PFD1235w/MAL7P1.1, MAL6P1.314, and MAL6P1.316)
or down-regulated (PF08_0107, PFD0995c, and PFA0015c).
We also determined copy numbers of three Group B genes
(PFL0005w, PFB1055c, and PFI1830c), a Group B/C gene
(PFL1950w), and PFE1640w (var1). The results (Table I)
were consistent with the threshold cycle (Ct) values and
confirmed the fold change calculations (Figs. 1 and 2).
Apart from two genes (PFI1830c and PFE1640w), the ex-
amined var genes were transcribed at higher levels in ring-
stage than in trophozoite/schizont-stage parasites, in agree-
ment with previous observations (35). These results also
show that selection-induced change from VSAUM toward
VSASM expression was accompanied by a change in var
gene transcription pattern from Group C genes toward
Group A and B/A genes. Thus, the Group C gene
PF08_0107 was both dominant and present in a much
higher copy number than any of the other transcripts
among unselected 3D7 (Figs. 1 and 2, and Table I),
whereas two Group A genes (PFD1235w/MAL7P1.1 and
MAL6P1.314) and a Group B/A gene (MAL6P1.316)
were dominant among antibody-selected 3D7 (Figs. 1 and
2, and Table I).
Northern blots of antibody-selected, ring-stage 3D7
showed strong hybridization signals corresponding to full-
length transcripts of the up-regulated genes PFD1235w/
MAL7P1.1 and MAL6P1.314 (Fig. 3, a and c). The corre-
sponding signals were either absent or much weaker in
Northern blots of unselected 3D7. By contrast, a strong
signal corresponding to PF08_0107, which was highly
transcribed but markedly down-regulated after antibody se-
lection, could be detected in unselected, but not in anti-
body-selected, 3D7 (Fig. 3 b).
These results suggest that 3D7 selected for expression of
VSASM-type antigens preferentially transcribes full-length
Group A var genes.
The Up-regulated Group A var Genes Are Translated into
High mol wt PfEMP1 in 3D7-expressing VSASM-type Anti-
gens. Western blot analysis of PfEMP1 expression by un-
selected late trophozoite/schizont-stage 3D7 using antise-
Figure 3. Relative levels of var transcripts in 10 g
total RNA obtained from unselected (1) and antibody-
selected 3D7 (2) ring-stage (30 h)–infected RBCs.
Northern blots were probed with DIG-labeled RNA
probes targeting PFD1235w/MAL7P1.1 (a), PF08_0107
(b), and MAL6P.314 (c). Transcript sizes were 12.5
(PFD1235w/MAL7P1.1), 8.3 (PF08_0107), and 5.7
kb (MAL6P.314). An ethidium bromide–stained gel is
shown to allow comparison of total RNA amounts (d).
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rum against the conserved intracellular ATS var domain
showed a single band with an estimated mol wt of 260 kD
(Fig. 4 a). This indicates that most of these parasites expressed
a PfEMP1 with a four-domain structure, in agreement
with our absolute quantification data (Table I), showing a
dominant Group C gene (PF08_0107) transcript encoding
a PfEMP1 molecule of this size. Antibody-selected 3D7
expressed a 260 kD PfEMP1, but also expressed additional
high mol wt PfEMP1 bands (Fig. 4 b). Again, the data
agree with the absolute quantification results showing
that the two most highly transcribed var genes in anti-
body-selected 3D7 were MAL6P1.316 and PFD1235w/
MAL7P1.1, encoding proteins with predicted mol wts of
330 and 400 kD, respectively. Furthermore, an antiserum
against DBL5-	 of PFD1235w/MAL7P1.1 revealed a high
mol wt band in SM1-, SM2-, and SM3-selected 3D7 (Fig.
4 d and unpublished data), corresponding to the top band
in the ATS-probed blot (Fig. 4 b). TrHBMEC-selected
parasites showed a three-band pattern identical to that of
the antibody-selected 3D7 when probed with anti-ATS se-
rum (unpublished data) and expressed the 400-kD gene
product of PFD1235w/MAL7P1.1 (Fig. 4 f). This indicates
that PFD1235w/MAL7P1.1 is translated into protein.
PFD1235w/MAL7P1.1-specific Antibodies Recognize An-
tigens on the Surface of VSASM-expressing 3D7. Antisera
against DBL5-	 of PFD1235w/MAL7P1.1 were tested on
infected RBCs by flow cytometry and confocal micros-
copy. Only a small minority of unselected 3D7 reacted
with the murine DBL5-	 antibodies (Fig. 4 a1), although
these infected RBCs did express VSA detectable by flow
Figure 4. Expression of PfEMP1
in unselected (a, c, and e), antibody-
selected (b and d), and TrHBMEC-
selected (f) trophozoite/schizont stage
3D7. Samples were run in 5% SDS-
PAGE gels, blotted, and probed
with antiserum against a conserved
part of the intracellular acidic segment
ATS (a and b) or against DBL5-	 of
PFD1235w/MAL7P1.1 (c–i). Anti-
body-selected parasites expressed
PFD1235w/MAL7P1.1 (***; b and
d) and a PfEMP1 with mol wt cor-
responding to the predicted mol wt
of MAL6P1.316 (**; b). Both selected
and unselected parasites expressed a
PfEMP1 with mol wt corresponding
to the predicted mol wt of PF08_0107
(*; a and b). TrHBMEC-selected 3D7
expressed PFD1235w/MAL7P1.1
(f). Western blots of SDS-extracted
RBCs infected by NF54 obtained
from a Dutch volunteer (reference
27) on days 8, 9, and 10 of an ex-
perimental, mosquito-induced in-
fection (g–i) probed with the
DBL5-	 antibody revealed expression
of PFD1235w/MAL7P1.1 on day
10 (i). Surface expression of antigens
in P. falciparum 3D7 before (a1–a4)
and after (b1–b4) antibody selection.
Murine plasma antiserum against re-
combinant DBL5-	 of PFD1235w/
MAL7P1.1 protein reacted with the
surface of most antibody-selected
3D7-infected RBCs in FACS® (b1,
green line). This reaction was abol-
ished by trypsin treatment (b1, purple
line). In contrast, the antiserum only
reacted with a minority of unselected
3D7 (a1, green line). Reactivity with
pre-vaccination mouse serum is
shown for comparison (shaded histo-
grams). VSA-specific IgG reactivity
in plasma from a semi-immune Afri-
can child (a2 and b2, red line) and a
clinically immune African adult (a2
and b2, blue line) confirmed the VSAUM phenotype of unselected 3D7 and the VSASM phenotype of antibody-selected 3D7. Localization of the
PFD1235w/MAL7P1.1 protein using confocal microscopy and murine plasma anti–DBL5-	 antibodies (a3, a4, b3, and b4). Ethidium bromide staining
of DNA in the nuclei is red/orange and staining of PFD1235w/MAL7P1.1 protein using FITC-labeled antibodies is green. Pre-vaccination mouse
plasma did not stain infected RBCs (not depicted).
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cytometry and human plasma (Fig. 4 a2). By contrast, these
antibodies recognized a large proportion of RBCs infected
with antibody-selected 3D7, a reactivity that was abrogated
by prior trypsin treatment of the infected RBCs (Fig. 4 b1).
Confocal microscopy using the DBL5-	 antiserum showed
a distinct punctate pattern on the surface of intact RBCs
infected by antibody-selected 3D7 (Fig. 4 b4), but not by
unselected 3D7 (Fig. 4 a4).
These results indicate that the product of PFD1235w/
MAL7P1.1 is expressed on the surface of antibody-selected
3D7 and is responsible for the VSASM phenotype.
VSASM-type Plasma IgG Recognition of PFD1235w/
MAL7P1.1 Protein. If PFD1235w/MAL7P1.1 mediates a
VSASM phenotype, a high proportion of children in ma-
laria-endemic areas would be expected to have acquired
antibodies to this protein. To test this hypothesis, we mea-
Figure 5. Plasma antibody levels to recombi-
nant DBL5-	 (a) and CIDR1-
 (b) domains of
the PFD1235w/MAL7P1.1 protein in Tanza-
nian children and adults, and in Danish donors
without P. falciparum exposure (DK). For com-
petition ELISA experiments, plates were coated
with recombinant CIDR1-
 domains of the
proteins encoded by PFD1235w/MAL7P1.1
(c) and PFE1640w/var1 (d), and ELISA reactiv-
ity was measured in three different plasma sam-
ples, which had been preincubated with in-
creasing concentrations of homologous or
heterologous fusion protein as indicated in the
top part of each panel. Nondepleted (ND)
plasma was included for comparison. Sequence
similarity between PFD1235w/MAL7P1.1 and
other genes of the var4 family were identified in
field isolates. Schematic domain structure of
PFD1235w/MAL7P1.1 (var4; e). The line in-
dicates the position of the 2.3-kb fragment (35
Ext) sequenced and numbered line (35) posi-
tion of the primer pair used for real-time PCR
(refer to Figs. 1 and 2, and Table I). Sequence
alignment of PFD1235w/MAL7P1.1, BM021,
and BM048 (f). The sequences shown corre-
spond to line 35 Ext in (e). These sequence data
are available from GenBank/EMBL/DDBJ un-
der accession nos. AY584238 and AY584239.
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sured IgG plasma levels against PFD1235w/MAL7P1.1 by
ELISA in asymptomatic individuals living under high ma-
laria transmission intensity in Tanzania. Most children and
adults had comparable levels of IgG directed against DBL5-	
(Fig. 5 a) and CIDR1-
 (Fig. 5 b). We used competi-
tion ELISA with CIDR1-
 domains from PFD1235w/
MAL7P1.1 and var1 (PFE1640w) to test the antigen speci-
ficity of the antibody recognition. Preincubation of the
plasma with homologous recombinant proteins caused a
dose-dependent reduction in OD492 values, whereas the
heterologous proteins did not (Fig. 5, c and d).
These results, and the demonstration that our DBL5-	
antiserum did not cross-react with MAL6P1.316 and
PF08_0107 in Western blotting, suggest that the antibody
reactivity to recombinant PFD1235w/MAL7P1.1 protein
was the result of exposure to parasites expressing PfEMP1
resembling that encoded by PFD1235w/MAL7P1.1, rather
than being due to a broad cross-reactivity between differ-
ent CIDR or DBL domains.
A Family of PFD1235w/MAL7P1.1 var Genes. Al-
though the exon I of many var genes differ markedly be-
tween different parasite isolates, conserved subfamilies such
as var1, var2, and var3 have been described (17, 28, 36, 37).
Therefore, we speculated that PFD1235w/MAL7P1.1 ho-
mologues might exist in isolates other than 3D7. Using
PFD1235w/MAL7P1.1-specific primers, we amplified a
2,292-bp fragment from genomic DNA of two Ghanaian
P. falciparum field isolates. These parasites carried genes
showing 72% identity to PFD1235w/MAL7P1.1 over a
stretch of 764 amino acids corresponding to the 3 end of
NTS into the 5 end of DBL2- (Fig. 5, e and f). We call
this new gene subfamily var4.
PFD1235w/MAL7P1.1 Is Up-regulated and Translated into
PfEMP1 Early in an NF54-induced Malaria Infection of a Non-
immune Patient. To examine the in vivo relevance of the
above findings, we studied parasites rescued on days 8, 9,
and 10 from a Dutch volunteer receiving a mosquito-
transmitted P. falciparum NF54 infection on day 0. NF54
was isolated from a Dutch malaria patient (26) and is
isogenic with 3D7 cloned from it (28). Western blots of
day 10 parasites probed with antiserum against the DBL5-	
domain of PFD1235w/MAL7P1 revealed a high mol wt
band (Fig. 4 i), corresponding to that observed in anti-
body- and TrHBMEC-selected 3D7 (Fig. 4, d and f). This
band was not detected in blots of parasites obtained on days
8 and 9 (Figs. 4, g and h). PFD1235w/MAL7P1.1 ap-
peared to be among the least transcribed var genes on day
8, ranking 55 out of 60 among day 8 ring-stage Ct values,
but ranked 9 out of 60 in parasites rescued on day 10. Fur-
thermore, the trophozoite copy numbers of PFD1235w/
MAL7P1.1 relative to seryl-tRNA synthetase indicated an
8.4-fold increase in PFD1235w/MAL7P1.1 mRNA be-
tween days 8 and 10.
Taken together, these data show that PFD1235w/
MAL7P1.1 is translated into a functional protein in vivo,
and indicate that this protein might be associated with fast-
growing parasites in nonimmune patients.
Discussion
Asexual P. falciparum parasitemia can be controlled by
antibodies acquired after natural exposure to the parasites
(38, 39). Several studies point to parasite-encoded, clonal
VSAs on the infected RBC surface as the main target of
these antibodies, as acquisition of protection from P. fal-
ciparum malaria corresponds to a gradual accumulation of
IgG with a broad range of VSA specificities (40–44). The
available evidence suggests that VSA-specific immune re-
sponses steadily restrict the repertoire of VSA that are com-
patible with parasite survival, and drive VSA expression
away from VSASM toward VSAUM (2, 3, 44, 45). Therefore,
VSA expression is nonrandom as it depends on the degree
of immunity in the infected host. In fact, several studies
have demonstrated that parasites causing severe P. falciparum
malaria in young children with little protective immunity
tend to express VSASM that are serologically distinct from
VSAUM expressed by most parasites causing uncomplicated
malaria and subclinical infection in older, and more im-
mune, individuals (2, 3). Importantly, VSASM appear to be
serologically less diverse than VSAUM (4), which is consis-
tent with the observation that immunity to severe malaria is
acquired more rapidly than to uncomplicated disease and
subclinical infection (46). This suggests that it might be
possible to develop disease-ameliorating vaccines that pro-
tect against mortality and severe morbidity by accelerating
acquisition of immunity to VSASM-expressing parasites and
forcing VSA expression away from VSASM. This study was
undertaken with that goal in mind.
The best characterized VSA is PfEMP1, which mediates
infected RBC adhesion to a number of host receptors and
is encoded by the var gene family (6–8). Attempts to iden-
tify VSASM-type PfEMP1 have been hampered by the in-
traclonal and interclonal variability of the var genes, the
concomitant transcription of several var genes during natural
infections, and the problem of primer bias (13–15). How-
ever, the entire genome of the P. falciparum clone 3D7 is
now available (16), making systematic quantitative analysis
of var gene transcription by real-time quantitative PCR and
absolute quantification possible for that clone. In vitro cul-
tures of 3D7 generally express VSAs that are serologically
similar to the VSAUM expressed by parasites causing un-
complicated disease, and bind strongly to CD36. However,
upon antibody selection (19) or selection for adhesion to
CD36 TrHBMEC, 3D7 expresses VSASM-like erythro-
cyte surface antigens.
We found that acquisition of the VSASM-type phenotype
in 3D7 was accompanied by a shift in var gene transcription
from dominant transcription of the Group C var gene
PF08_0107 to dominant transcription of the Group A
genes PFD1235w/MAL7P1.1 and MAL6P1.314, and the
Group B/A gene MAL6P1.316. Northern blot data docu-
mented that the transcripts were full-length and the ex-
pressed products of several high mol wt PfEMP1 species,
including PFD1235w/MAL7P1.1, could be detected in
antibody-selected 3D7 by Western blotting. Finally, we
could detect a VSA on the surface of antibody-selected
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3D7-infected RBCs using a murine antiserum raised
against recombinant DBL5-	 domain of the PFD1235w/
MAL7P1.1 var. This finding directly points to the protein
product of the Group A var gene PFD1235w/MAL7P1.1
as a major VSASM-type antigen.
Thus, it appears that Group A and B/A genes such as
PFD1235w/MAL7P1.1, MAL6P1.314, and MAL6P1.316
encode VSASM-like proteins, and that these proteins are in-
volved in the acquisition of the VSASM phenotype after anti-
body selection or selection for adhesion to TrHBMEC. The
fact that almost identical results were obtained using several
plasma pools from children living in East and West Af-
rica indicate that PfEMP1 similar to those encoded by
PFD1235w/MAL7P1.1, MAL6P1.314, and MAL6P1.316
exist in P. falciparum parasites transmitted across Africa. This
observation and the findings that Group A is structurally the
most homogeneous of the var gene groups (17, 18) are con-
sistent with the hypothesis that SM-type VSAs are antigeni-
cally relatively conserved (4, 19). Other characteristics of the
Group A var genes further support their proposed relation to
VSASM. Thus, most Group A var genes encode high mol wt
PfEMP1 molecules that do not bind CD36 (18, 47). Ex-
pression of high mol wt PfEMP1 has been linked to severe
malaria (48), and selection of 3D7 for expression of VSASM
causes decreased adhesiveness to CD36 (19). Furthermore,
Group A genes encode a characteristic head structure that
includes a DBL1-
 homology block lacking one to two
cysteines, a feature that has been linked to severe malaria
(15). The Group B/A gene MAL6P1.316 is unusually
Group A–like in that it has a 5 UTR region with low sim-
ilarity to Group B genes as well as a complex domain struc-
ture and a DBL1-CIDR1 head structure that is characteris-
tic of Group A rather than Group B var genes (18).
Immuno-epidemiological evidence suggests that the
gradual acquisition of protective immunity steadily
drives VSA expression from VSASM toward VSAUM. The
proposed relationship between VSASM expression and
PFD1235w/MAL7P1.1 implies that the product of this
gene should be recognized at high levels and early in life.
Consistent with this hypothesis, we found that Tanzanian
young children and adolescents had comparable levels of
IgG reacting with recombinant PFD1235w/MAL7P1.1
DBL5-	 and CIDR1-
 domains.
We have proposed that the dominance of parasites ex-
pressing VSASM-type antigens among nonimmune patients is
related to their higher growth rate in such individuals and
that the shift toward VSAUM-type antigens occurs as this
strong selective advantage of VSASM-expressing parasites
gradually disappears as VSASM-specific immunity is acquired
(5). In line with this hypothesis, we found that transcription
of PFD1235w/MAL7P1.1 was much higher on day 10 of
infection compared with earlier time points in a Dutch non-
immune volunteer infected by P. falciparum, indicating that a
larger proportion of the parasites obtained on day 10 tran-
scribed PFD1235w/MAL7P1.1 than earlier in the infection.
Any malaria vaccine candidate must meet the fundamen-
tal requirement that it should be a well-defined and not too
polymorphic antigen. In general, var genes are believed
to vary considerably between different parasite isolates,
although exceptions have been recently described (17,
28, 36, 37). We found genes with a high similarity to
PFD1235w/MAL7P1.1 in parasites from patients and sug-
gest that this new conserved var gene subfamily should be
named var4.
In conclusion, we have identified 3D7 var genes confer-
ring a VSASM phenotype associated with severe and life-
threatening malaria. Furthermore, we have shown that
one of the most highly transcribed Group A var genes
(PFD1235w/MAL7P1.1) is conserved and translated into
protein, which can be detected on the surface of infected
erythrocytes carrying the VSASM phenotype. Finally, we
have shown that recombinant domains of PFD1235w/
MAL7P1.1 are well recognized by antibodies in plasma
from P. falciparum–exposed children, and that transcription
of this Group A gene dominates among 3D7 parasites early
in the infection of a nonimmune individual. Our data sug-
gest that it is possible to develop a disease-ameliorating
vaccine against severe P. falciparum malaria that is based
on proteins encoded by Group A var genes such as
PFD1235w/MAL7P1.1.
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